Related Experiment Video

Updated: Aug 15, 2025

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.3K

Case report: olaparib use in metastatic lung adenocarcinoma with BRCA2 pathogenic variant

Jonathan Soon Jian Hao1, Chan Sock Hoai1, Daniel Tan Shao Weng2,3

  • 1Cancer Genetics Service, National Cancer Centre Singapore, Singapore 169610, Singapore.

Cold Spring Harbor Molecular Case Studies
|December 28, 2022
PubMed

Insights

Poly (ADP-ribose) polymerase (PARP) inhibitors show promise in treating lung adenocarcinoma with somatic BRCA2 mutations. Next-generation sequencing can identify these mutations for targeted therapy selection.

Area of Science:

  • Oncology
  • Genetics
  • Pharmacology

Background:

  • Poly (ADP-ribose) polymerase (PARP) inhibitors are approved for cancers with germline BRCA1/BRCA2 mutations.
  • Their efficacy in cancers without germline BRCA1/BRCA2 alterations is less understood.
  • Non-small-cell lung cancer (NSCLC) can exhibit somatic BRCA1/BRCA2 alterations.

Observation:

  • A patient with metastatic lung adenocarcinoma presented with a somatic BRCA2 pathogenic variant.
  • The patient received olaparib, a PARP inhibitor, as treatment.
  • The treatment with olaparib was effective for the patient.

Findings:

  • This case report details the successful treatment of lung adenocarcinoma with a somatic BRCA2 mutation using olaparib.
  • The study discusses current data on PARP inhibitor use in NSCLC.
  • Next-generation sequencing (NGS) is highlighted as crucial for identifying actionable molecular alterations.

Implications:

  • Somatic BRCA2 mutations in NSCLC may represent a target for PARP inhibitor therapy.
  • NGS is a valuable tool for guiding personalized treatment strategies in lung cancer.
  • This approach can lead to improved outcomes for patients with specific molecular profiles.
Keywords:
chronic lung disease

More Related Videos

Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells09:24

Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells

Published on: August 12, 2015

9.2K
Evaluating In Vitro DNA Damage Using Comet Assay10:43

Evaluating In Vitro DNA Damage Using Comet Assay

Published on: October 11, 2017

37.9K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K